公开(公告)号：WO2021195553A1

公开(公告)日：2021-09-30

申请号：PCT/US2021/024467

申请日：2021-03-26

申请人： ESPERANCE PHARMACEUTICALS, INC

发明人： LEUSCHNER, Carola ,  ALILA, Hector ,  SOOD, Anil ,  KIM, Mark

IPC分类号： A61K38/00 ,  A61K38/10 ,  A61K38/16 ,  A61P35/00 ,  C07K7/08 ,  C07K14/00 ,  C07K14/72 ,  C07K16/28

摘要： The invention relates to fusion constructs and checkpoint inhibitors, methods of using fusion constructs and checkpoint inhibitors, and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies.

公开(公告)号：WO2021189019A1

公开(公告)日：2021-09-23

申请号：PCT/US2021/023353

申请日：2021-03-19

申请人： KEROS THERAPEUTICS, INC.

发明人： SEEHRA, Jasbir, S. ,  LACHEY, Jennifer ,  TSENG, Claire ,  O'NEILL, Jason ,  THØGERSEN, Henning ,  FURUTANI, Elissa

IPC分类号： A61K38/00 ,  A61K38/16 ,  A61K38/17 ,  A61K38/18 ,  A61K47/68 ,  C07K14/705

摘要： The invention features polypeptides that include an extracellular ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII chimera fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, and/or pulmonary hypertension.

公开(公告)号：WO2021187380A1

公开(公告)日：2021-09-23

申请号：PCT/JP2021/010137

申请日：2021-03-12

申请人： 国立大学法人大阪大学

发明人： 肥後　修一朗 ,  彦惣　俊吾 ,  宮川　繁 ,  澤　芳樹 ,  坂田　泰史

IPC分类号： A61K48/00 ,  A61P9/06 ,  A61P21/00 ,  C12N5/074 ,  C12Q1/02 ,  A61K38/16

摘要： 本発明は、遺伝子変異に起因する不整脈源性心筋症患者の心筋細胞に、遺伝子変異を有する遺伝子に対応する正常遺伝子を送達して正常タンパク質を発現させるための遺伝子治療薬を有効成分とする不整脈源性心筋症治療用医薬を提供する。また、本発明は、プラコフィリン２遺伝子またはデスモグレイン２遺伝子の変異に起因する不整脈源性心筋症患者の細胞から樹立された多能性幹細胞を提供する。

公开(公告)号：WO2021185969A1

公开(公告)日：2021-09-23

申请号：PCT/EP2021/056949

申请日：2021-03-18

申请人： NUMAFERM GMBH

发明人： SCHWARZ, Christian

IPC分类号： A61K38/16

摘要： The present invention relates to polypeptides comprising hemolysin A (HlyA) fragments and/or variants and a peptide or polypeptide of interest in form of a fusion protein that exhibits improved expression and secretion as well as increased solubility and stability and improved renaturation efficiency. Also encompassed are nucleic acids encoding these polypeptides, host cells that comprise said nucleic acids, and methods and uses for protein expression using said nucleic acids, host cells and polypeptides.

公开(公告)号：WO2021183786A2

公开(公告)日：2021-09-16

申请号：PCT/US2021/021945

申请日：2021-03-11

申请人： UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED

发明人： HOH, Brian, Lim ,  BATICH, Christopher, D. ,  HOSAKA, Koji

IPC分类号： A61F2/82 ,  A61K38/16 ,  A61K38/20

摘要： The present disclosure provides for methods, devices, and compositions for controlling factors involved in the healing of lesions. The methods, devices, and composition include a first therapeutic agent which includes an amount of MCP-1 and/or osteopontin effective to promote recruitment of macrophages to the lesion site. In additional embodiments, there is further provided a second therapeutic agent which includes an inhibitor of at least one of IL-17A, CXCL1, or IL-6 to promote polarization of an amount of the macrophages to M2 phenotype macrophages at the lesion site.

公开(公告)号：WO2021182901A1

公开(公告)日：2021-09-16

申请号：PCT/KR2021/003052

申请日：2021-03-11

申请人： 연세대학교 산학협력단

发明人： 허만욱 ,  박수진 ,  송지양 ,  최서현

IPC分类号： A61K38/16 ,  A61P3/06 ,  A61P1/16 ,  A61P3/10 ,  A23L33/195

摘要： 본 발명은 일정 길이의 내부 잔기가 지방족 아미노 카르복실산으로 치환된 Tat 펩타이드 변이체를 유효성분으로 포함하는 대사질환의 예방 또는 치료용 약제학적 조성물 및 기능성 식품 조성물에 관한 것이다. 본 발명의 조성물은 천연의 Tat 펩타이드의 지방 감소 효능을 그대로 유지하면서도 수용성 및 수율이 현저하게 상승하여, 생산이 보다 용이하고 보다 생체적합성이 뛰어난 대사질환 치료제 조성물로 유용하게 이용될 수 있다.

公开(公告)号：WO2021178975A1

公开(公告)日：2021-09-10

申请号：PCT/US2021/021411

申请日：2021-03-08

申请人： ALBERT EINSTEIN COLLEGE OF MEDICINE

发明人： GOLDSTEIN, Harris ,  ALMO, Steven C. ,  GARFORTH, Scott ,  LI, Mengyan

IPC分类号： A61K31/7088 ,  A61K35/76 ,  A61K35/761 ,  A61K38/16 ,  A61K39/00 ,  A61K39/002

摘要： The present disclosure relates to a method of modulating one or more genetically modified cells, e.g., chimeric antigen receptor (CAR)-expressing cells, ex vivo and/or in vivo.

公开(公告)号：WO2021168122A1

公开(公告)日：2021-08-26

申请号：PCT/US2021/018590

申请日：2021-02-18

申请人： INSTITUTE FOR SYSTEMS BIOLOGY ,  HEATH, James R. ,  CHOUR, William ,  ZHANG, Rongyu

发明人： HEATH, James R. ,  CHOUR, William ,  ZHANG, Rongyu

IPC分类号： A61K38/16 ,  A61P37/02 ,  A61P37/04

摘要： Peptide-major histocompatibility (MHC) Class II nucleic acids and proteins are provided. Methods of their use, for example in methods of identifying antigen-specific T cells and adoptive cell therapy, are also provided.

公开(公告)号：WO2021164677A1

公开(公告)日：2021-08-26

申请号：PCT/CN2021/076437

申请日：2021-02-10

申请人： 成都奥达生物科技有限公司

发明人： 周述靓 ,  王鹏 ,  邓岚

IPC分类号： C07K7/08 ,  C07K7/06 ,  A61K38/16 ,  A61P11/00 ,  A61P31/14

摘要： 提供了一种抗合胞病毒(RSV)膜融合抑制剂，属于医药合成领域。本发明的抗合胞病毒膜融合抑制剂可用于治疗疾病，如合胞病毒肺炎。

公开(公告)号：WO2021163466A1

公开(公告)日：2021-08-19

申请号：PCT/US2021/017838

申请日：2021-02-12

申请人： CHILDREN'S NATIONAL MEDICAL CENTER

发明人： LIU, Yang ,  WANG, Yin ,  LIU, Yan ,  BAILEY, Christopher

IPC分类号： A61P35/02 ,  A61P37/02 ,  A61K35/74 ,  A61K9/127 ,  A61K38/16 ,  A61K47/69

摘要： The present invention relates to treating TP53-mutated AML using a Hypoxia-Inducible Factor (HIF inhibitor). The invention further relates to a new HIF inhibitor formulation with longer half-life and significantly improved therapeutic effect for TP53-mutated AML.